ArticleCureus2026
Burden of Multidrug-Resistant Uropathogens and Their Antimicrobial Susceptibility Among Hospitalized Patients: A Single-Center Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Urinary tract infections (UTIs) represent a major global health challenge, with the rise of multidrug-resistant (MDR) uropathogens significantly complicating empiric treatment and increasing medical costs. The objective of this study was to determine the local burden of MDR UTIs and the patient characteristics associated with it, characterize the causative pathogens, and describe their antimicrobial susceptibility patterns in a community hospital setting. Methods A retrospective cross-sectional study was conducted at Phelps Hospital in Sleepy Hollow, NY, USA, utilizing 392 urine samples collected from inpatients between February and May 2026. MDR status was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Bacterial isolates were identified using automated methods, followed by antimicrobial susceptibility testing interpreted according to Clinical and Laboratory Standards Institute (CLSI) 2022 guidelines. Results Among 286 symptomatic patients, 70 (70/286; 24.47%) had MDR UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.